No Data
No Data
Firebrick Pharma Launches Nasodine Nasal Spray in Singapore
Firebrick Pharma (ASX:FRE) has launched its Nasodine Nasal Spray in Singapore, making the product the first povidone-iodine nasal spray in the country, according to a Thursday filing with the Australi
Firebrick Pharma Raises AU$800,000 via Placement
Firebrick Pharma (ASX:FRE) received binding commitments for a placement of AU$800,000 from a substantial shareholder, comprising 16 million shares at a discounted price of AU$0.05 apiece, according to
Firebrick Pharma Sees Substantial Holder up Stake to 12% in Placement
Betadine-like nasal spray provider Firebrick Pharma (ASX:FRE) – whose flagship product Nasodine has recently gone live for sale in the US – has raised $0.8M in a placement largely backed by an existing substantial holder.
Firebrick Pharma Appoints Auditor
Firebrick Pharma (ASX:FRE) appointed BDO Audit as company auditor, according to a Monday filing with the Australian bourse. The appointment follows the resignation of BDO Audit (WA) in line with the f
Firebrick Pharma Launches Antiseptic Nasal Spray Into US Online Market
An antiseptic nasal spray developed by Melbourne-based Firebrick Pharma (ASX: FRE) to attack the common cold has been officially launched online for US customers.
Stocks of the Hour: Firebrick Pharma, Critical Resources, Blue Star Helium
Firebrick Pharma (ASX:FRE) has announce that its Nasodine Nasal Spray product is being launched in the United States today. The product will be promoted for "nasal hygiene" without any therapeutic cla
No Data